Vanda Pharmaceuticals (VNDA) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -7.60% |
| Jun 30, 2025 | -7.25% |
| Mar 31, 2025 | -5.51% |
| Dec 31, 2024 | -4.83% |
| Sep 30, 2024 | -2.52% |
| Jun 30, 2024 | -0.75% |
| Mar 31, 2024 | 1.78% |
| Dec 31, 2023 | 2.29% |
| Sep 30, 2023 | 1.97% |
| Jun 30, 2023 | 3.61% |
| Mar 31, 2023 | 6.67% |
| Dec 31, 2022 | 6.34% |
| Sep 30, 2022 | 7.01% |
| Jun 30, 2022 | 7.60% |
| Mar 31, 2022 | 16.19% |
| Dec 31, 2021 | 12.41% |
| Sep 30, 2021 | 13.47% |
| Jun 30, 2021 | 12.52% |
| Mar 31, 2021 | 11.52% |
| Dec 31, 2020 | 11.22% |
| Sep 30, 2020 | 8.75% |
| Jun 30, 2020 | 8.22% |
| Mar 31, 2020 | 15.19% |
| Dec 31, 2019 | 17.60% |
| Sep 30, 2019 | 19.28% |
| Jun 30, 2019 | 16.53% |
| Mar 31, 2019 | 18.70% |
| Dec 31, 2018 | 14.93% |
| Sep 30, 2018 | 13.33% |
| Jun 30, 2018 | 19.71% |
| Mar 31, 2018 | 19.30% |
| Dec 31, 2017 | 8.20% |
| Sep 30, 2017 | 36.91% |
| Jun 30, 2017 | 17.46% |
| Mar 31, 2017 | 10.15% |
| Dec 31, 2016 | 9.80% |
| Sep 30, 2016 | 10.86% |
| Jun 30, 2016 | 9.38% |
| Mar 31, 2016 | 7.15% |
| Dec 31, 2015 | 7.17% |
| Sep 30, 2015 | 18.37% |